New drug price re-evaluation system will affect sales of domestic pharmaceutical industry

The envisaged drug price re-evaluation system seems likely to significantly affect large-sized and foreign-invested pharmaceutical firms rather than medium- and small-sized firms, according to Hanyang Securities.

Hanyang Securities said that under the new system, 31 foreign-invested firms will greatly suffer from average reduction of 7.30 percent (6.8 items) in drug prices, followed by the ...